Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Nanoengineered particles for enhanced cancer radiotherapy

Project description

Improved radiotherapy with nanoparticles

External beam radiotherapy (EBRT) is a common cancer treatment that uses high-energy radiation, typically X-rays, to target and destroy cancer cells. The radiation is delivered from outside the body with beams focusing on the tumour to minimise damage to surrounding healthy tissues. To enhance the effects of EBRT, the ERC-funded ENCANT project proposes the development of nanoparticles containing high atomic number (Z) elements such as gold or platinum. These elements increase the absorption of radiation in tumour tissue by interacting with X-rays due to their dense electron clouds. These nanoparticles will be engineered for optimal blood circulation and will allow for lower radiation doses, reducing the adverse effects of radiotherapy.

Objective

Current cancer research efforts are focused on obtaining targeted therapies, with greater precision, that lead to improved patient survival, with fewer adverse effects to ensure a better quality of life. ENCANT (nanoengineered particles for ENhanced CANcer radioTherapy) will contribute to this aim by developing new therapeutic agents based on biocompatible nanoparticles bearing high atomic number (Z) elements, which will enhance external beam radiotherapy (EBRT) effect on cancer tissue. This will allow the use of a lower radiation dose, consequently lowering adverse effects related to radiotherapy lack of specificity.

The physicochemical properties of the NPs can be rationally designed according to different needs. NPs will be functionalized to increase their blood circulation time and facilitate their accumulation in the tumoural tissue. NPs will be tested in vivo to describe toxicity ranges, targeting efficiency and their therapeutic effect with external beam radiotherapy using in vivo cancer models.

ENCANT will initially focus on high-Z NPs for prostate cancer (PC). Nevertheless, their adaptability should allow to use them for other tumour types, thus expanding their range of application. ENCANT aims to improve and expand oncology treatment options available to cancer patients thus providing them a more personalized treatment.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 130 000,00
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)